✦ LIBER ✦

Natural history of skeletal disease in multiple myelomatosis and treatment with clodronate

✍ Scribed by McCloskey, EV; O'Rourke, N; MacLennan, I; Chapman, C; Beneton, M; Greaves, M; Preston, FE; Kanis, JA

Book ID: 122832522
Publisher: Elsevier Science
Year: 1992
Tongue: English
Weight: 163 KB
Volume: 17
Category: Article
ISSN: 0169-6009
DOI: 10.1016/0169-6009(92)92315-H

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

775 Effect of clodronate on progression

775 Effect of clodronate on progression of skeletal disease in multiple myelomatosis

✍ E.V. McCloskey; I.C.M. MacLennan; M. Drayson; C. Chapman; J. Dunn; J.A. Kanis 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Treatment of skeletal disease in breast

Treatment of skeletal disease in breast cancer with clodronate

✍ Paterson, A.H.G.; Ernst, D.S.; Powles, T.J.; Ashley, S.; McCloskey, E.V.; Kanis, 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 620 KB

The natural history of vascular disease

The natural history of vascular disease in homocystinuria and the effects of treatment

✍ D. E. L. Wilcken; B. Wilcken 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 17 KB

Issues in the natural history and treatm

Issues in the natural history and treatment of coronary heart disease in black populations: Surgical treatment

✍ Albert Oberman; Gary Cutter 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 817 KB

Magnetic resonance in monitoring the nat

Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment

✍ M. Filippi; M. Rovaris; G. Comi 📂 Article 📅 1996 🏛 Springer Milan 🌐 English ⚖ 886 KB

Parkinsonism in multiple system atrophy:

Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease

✍ François Tison; Farid Yekhlef; Virginie Chrysostome; Eric Balestre; Niall P. Qui 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

We analyzed parkinsonian features in multiple system atrophy (MSA) compared with age- and disease duration-matched Parkinson's disease (PD) patients, and assessed the applicability of the Unified Parkinson's Disease Rating Scale (UPDRS) -III motor scale as a means of rating their severity. Cross-sec